467 related articles for article (PubMed ID: 30039289)
1. Challenges and Opportunities of Neoadjuvant Treatment in Locally Advanced Melanoma.
McKean MA; Amaria RN
Am J Clin Dermatol; 2018 Oct; 19(5):639-646. PubMed ID: 30039289
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant Treatment of Melanoma: Recent Developments and Future Perspectives.
Testori AAE; Ribero S; Indini A; Mandalà M
Am J Clin Dermatol; 2019 Dec; 20(6):817-827. PubMed ID: 31177507
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Immunotherapy for Locally Advanced Melanoma.
Pelster MS; Amaria RN
Curr Treat Options Oncol; 2020 Feb; 21(2):10. PubMed ID: 32025932
[TBL] [Abstract][Full Text] [Related]
4. Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB-IV M1c melanoma patients.
Fröhlich A; Niebel D; Fietz S; Egger E; Buchner A; Sirokay J; Landsberg J
Cancer Immunol Immunother; 2020 May; 69(5):759-769. PubMed ID: 32052079
[TBL] [Abstract][Full Text] [Related]
5. The Emerging Role of Surgery for Patients With Advanced Melanoma Treated With Immunotherapy.
Puza CJ; Bressler ES; Terando AM; Howard JH; Brown MC; Hanks B; Salama AKS; Beasley GM
J Surg Res; 2019 Apr; 236():209-215. PubMed ID: 30694757
[TBL] [Abstract][Full Text] [Related]
6. Impact of Circulating and Tissue Biomarkers in Adjuvant and Neoadjuvant Therapy for High-Risk Melanoma: Ready for Prime Time?
Indini A; Roila F; Grossi F; Massi D; Mandalà M
Am J Clin Dermatol; 2021 Jul; 22(4):511-522. PubMed ID: 34036489
[TBL] [Abstract][Full Text] [Related]
7. Rationale for New Checkpoint Inhibitor Combinations in Melanoma Therapy.
Mandalà M; Tondini C; Merelli B; Massi D
Am J Clin Dermatol; 2017 Oct; 18(5):597-611. PubMed ID: 28432648
[TBL] [Abstract][Full Text] [Related]
8. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma.
Tetzlaff MT; Messina JL; Stein JE; Xu X; Amaria RN; Blank CU; van de Wiel BA; Ferguson PM; Rawson RV; Ross MI; Spillane AJ; Gershenwald JE; Saw RPM; van Akkooi ACJ; van Houdt WJ; Mitchell TC; Menzies AM; Long GV; Wargo JA; Davies MA; Prieto VG; Taube JM; Scolyer RA
Ann Oncol; 2018 Aug; 29(8):1861-1868. PubMed ID: 29945191
[TBL] [Abstract][Full Text] [Related]
9. Patterns of disease control and survival in patients with melanoma brain metastases undergoing immune-checkpoint blockade.
Milsch L; Gesierich A; Kreft S; Livingstone E; Zimmer L; Goebeler M; Schadendorf D; Schilling B
Eur J Cancer; 2018 Aug; 99():58-65. PubMed ID: 29906735
[TBL] [Abstract][Full Text] [Related]
10. First person: Antoni Ribas, MD, PhD: The physician-scientist from the University of California at Los Angeles researches how new therapies for patients with advanced malignant melanoma can help to overcome resistance to treatment.
Printz C
Cancer; 2018 Mar; 124(6):1097-1098. PubMed ID: 29509327
[No Abstract] [Full Text] [Related]
11. Tackling melanoma by adjuvant therapy: why, whom and how?
Schilling B; Wiesner T
Br J Dermatol; 2019 Jan; 180(1):1-2. PubMed ID: 30604551
[No Abstract] [Full Text] [Related]
12. The emerging role of immune checkpoint based approaches in AML and MDS.
Boddu P; Kantarjian H; Garcia-Manero G; Allison J; Sharma P; Daver N
Leuk Lymphoma; 2018 Apr; 59(4):790-802. PubMed ID: 28679300
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer.
Puri S; Shafique M; Gray JE
Curr Treat Options Oncol; 2018 Jun; 19(8):39. PubMed ID: 29931587
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous Melanoma - A Review of Systemic Therapies.
Lee KA; Nathan P
Acta Derm Venereol; 2020 Jun; 100(11):adv00141. PubMed ID: 32346745
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach.
Davar D; Tarhini AA; Kirkwood JM
Clin Dermatol; 2013; 31(3):237-50. PubMed ID: 23608443
[TBL] [Abstract][Full Text] [Related]
16. KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma.
Luke JJ; Ascierto PA; Carlino MS; Gershenwald JE; Grob JJ; Hauschild A; Kirkwood JM; Long GV; Mohr P; Robert C; Ross M; Scolyer RA; Yoon CH; Poklepovic A; Rutkowski P; Anderson JR; Ahsan S; Ibrahim N; M Eggermont AM
Future Oncol; 2020 Jan; 16(3):4429-4438. PubMed ID: 31870188
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of concurrent immunoradiotherapy in patients with metastatic melanoma after progression on nivolumab.
Nomura M; Otsuka A; Yoshimura M; Nonomura Y; Kaku Y; Matsumoto S; Muto M
Cancer Chemother Pharmacol; 2018 May; 81(5):823-827. PubMed ID: 29502140
[TBL] [Abstract][Full Text] [Related]
18. New NCCN Guidelines for Uveal Melanoma and Treatment of Recurrent or Progressive Distant Metastatic Melanoma.
Barker CA; Salama AK
J Natl Compr Canc Netw; 2018 May; 16(5S):646-650. PubMed ID: 29784747
[TBL] [Abstract][Full Text] [Related]
19. Recent breakthroughs in metastatic uveal melanoma: a cause for optimism?
Sacco JJ; Kalirai H; Kenyani J; Figueiredo CR; Coulson JM; Coupland SE
Future Oncol; 2018 Jun; 14(14):1335-1338. PubMed ID: 29741103
[No Abstract] [Full Text] [Related]
20. The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients.
Eggermont AMM; Dummer R
Eur J Cancer; 2017 Nov; 86():101-105. PubMed ID: 28968566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]